| HOME >> MEDICINE >> TECHNOLOGY |
$
254,162,220$
248,892,575LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Short-term bank loans
$
4,752,000$
11,018,000Accounts payable 4,149,0254,996,463Due to related parties 5,818,2423,319,938Other payables and accrued expenses 22,592,19530,661,794Advance from customers 4,532,1534,365,523Advance from customers – a related party 1,017,322486,602Income tax payable 3,841,8035,373,633Other taxes payable 2,434,0342,189,913Derivative liabilities - warrants 4,201,0375,410,419Total Current Liabilities 53,337,81167,822,285Other payable 345,127343,477Deferred tax liabilities 1,580,6981,685,772Total Liabilities 55,263,63669,851,534Stockholders' Equity Common stock: par value $.0001; 100,000,000 shares authorized; 25,601,125 shares
issued and outstanding at March 31, 2012 and December 31, 2011 2,5602,560Additional paid-in capital 49,800,73048,838,311Retained earnings 86,878,11773,920,811Accumulated other comprehensive income 13,672,66512,750,682Total stockholders' equity attributable to China Biologic Products, Inc. 150,354,072135,512,364Noncontrolling interest 48,544,51243,528,677Total Equity 198,898,584179,041,041Commitments and contingencies --Total Liabilities and Equity
$
254,162,220$
248,892,575
CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS For the three months ended March 31, 2012 March 31, 2011 CASH FLOWS FROM OPERATING ACTIVITIES:Net income
$
17,718,167$
9,828,200A
'/>"/>
| SOURCE China Biologic Products, Inc. Copyright©2010 PR Newswire. All rights reserved |